Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Plus Therapeutics Inc (PSTV)

Plus Therapeutics Inc (PSTV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 36,815
  • Shares Outstanding, K 171,551
  • Annual Sales, $ 5,210 K
  • Annual Income, $ -22,390 K
  • EBIT $ -15 M
  • EBITDA $ -15 M
  • 60-Month Beta 0.78
  • Price/Sales 7.57
  • Price/Cash Flow N/A
  • Price/Book 7.99
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.61
  • Most Recent Earnings $0.00 on 03/12/26
  • Next Earnings Date 05/29/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.04
  • Number of Estimates 2
  • High Estimate $-0.03
  • Low Estimate $-0.04
  • Prior Year $-0.56
  • Growth Rate Est. (year over year) +92.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1600 +1.62%
on 03/31/26
0.3280 -50.43%
on 03/12/26
-0.1401 (-46.28%)
since 02/27/26
3-Month
0.1600 +1.62%
on 03/31/26
0.6130 -73.47%
on 01/07/26
-0.4173 (-71.96%)
since 12/26/25
52-Week
0.1600 +1.62%
on 03/31/26
1.2200 -86.67%
on 04/23/25
-0.9974 (-85.98%)
since 03/28/25

Most Recent Stories

More News
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals...

PSTV : 0.1626 (-24.23%)
Plus Therapeutics Announces Reverse Stock Split 

HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies...

PSTV : 0.1626 (-24.23%)
Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors

HOUSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals...

PSTV : 0.1626 (-24.23%)
Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%

HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals...

PSTV : 0.1626 (-24.23%)
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

HOUSTON, March 12, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals...

PSTV : 0.1626 (-24.23%)
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™

HOUSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals...

PSTV : 0.1626 (-24.23%)
Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization

HOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals...

PSTV : 0.1626 (-24.23%)
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET

HOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals...

PSTV : 0.1626 (-24.23%)
Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering

HOUSTON, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals...

PSTV : 0.1626 (-24.23%)

Business Summary

Plus Therapeutics Inc. is a clinical-stage pharmaceutical company. It engages in developing treatments for cancer and other diseases primarily in the United States. The company's product candidate consists of DocePLUS which are in clinical stage. Plus Therapeutics Inc., formerly known as Cytori Therapeutics...

See More

Key Turning Points

3rd Resistance Point 0.2441
2nd Resistance Point 0.2363
1st Resistance Point 0.2255
Last Price 0.1626
1st Support Level 0.2069
2nd Support Level 0.1991
3rd Support Level 0.1883

See More

52-Week High 1.2200
Fibonacci 61.8% 0.8151
Fibonacci 50% 0.6900
Fibonacci 38.2% 0.5649
Last Price 0.1626
52-Week Low 0.1600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.